Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Simple item page
dc.contributor.authorDruker, B.
dc.contributor.authorGuilhot, F.
dc.contributor.authorO'Brien, S.
dc.contributor.authorGathmann, I.
dc.contributor.authorKantarjian, H.
dc.contributor.authorGattermann, N.
dc.contributor.authorDeininger, M.
dc.contributor.authorSilver, R.
dc.contributor.authorGoldman, J.
dc.contributor.authorStone, R.
dc.contributor.authorCervantes, F.
dc.contributor.authorHochhaus, A.
dc.contributor.authorPowell, B.
dc.contributor.authorGabrilove, J.
dc.contributor.authorRousselot, P.
dc.contributor.authorReiffers, J.
dc.contributor.authorCornelissen, J.
dc.contributor.authorHughes, T.
dc.contributor.authorAgis, H.
dc.contributor.authorFischer, T.
dc.contributor.authoret al.
dc.date.issued2006
dc.description© 2009 Massachusetts Medical Society
dc.description.abstractBackground The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. Methods We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. Results The median follow-up was 60 months. Kaplan–Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. Conclusions After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
dc.description.statementofresponsibilityBrian J. Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop Kantarjian, Norbert Gattermann, Michael W.N. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak and Richard A. Larson
dc.identifier.citationNew England Journal of Medicine, 2006; 355(23):2408-2417
dc.identifier.doi10.1056/NEJMoa062867
dc.identifier.issn0028-4793
dc.identifier.issn1533-4406
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.urihttp://hdl.handle.net/2440/35690
dc.language.isoen
dc.publisherMassachusetts Medical Soc
dc.source.urihttp://content.nejm.org/cgi/content/short/355/23/2408
dc.subjectIRIS Investigators
dc.subjectHumans
dc.subjectBenzamides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectInterferon-alpha
dc.subjectFusion Proteins, bcr-abl
dc.subjectCytarabine
dc.subjectAntineoplastic Agents
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectSurvival Rate
dc.subjectSurvival Analysis
dc.subjectFollow-Up Studies
dc.subjectFemale
dc.subjectMale
dc.subjectProtein-Tyrosine Kinases
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subjectKaplan-Meier Estimate
dc.subjectImatinib Mesylate
dc.titleFive-year follow-up of patients receiving imatinib for chronic myeloid leukemia
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications